Dr. Traugott Ullrich to Lead New Business Unit: Innovation & Market Access at Schwabe Group
2026-02-02
As part of our ongoing organizational development, the Schwabe Group is combining Research & Development and Global Regulatory Affairs into a new business unit: Innovation and Market Access.
This strategic move aims to:
✅ Secure and expand the market presence of our products
✅ Drive customer- and market-focused development of new health solutions in close alignment with Marketing and Sales
✅ Ensure rapid market access for innovative offerings
Additionally, the new unit will coordinate the Schwabe Group’s national and European pharma policy activities to maintain and strengthen optimal regulatory and political conditions for our business model.
We are pleased to announce that Dr. Traugott Ullrich will lead this new division as EVP Innovation & Market Access, effective February 1, 2026, reporting directly to Olaf Schwabe, CEO of the Schwabe Group.
Dr. Ullrich combines profound medical knowledge with extensive commercial expertise. Working for many years successfully as a Board Member in national and European Pharmaceutical Associations (AESGP, Pharma Deutschland) he can complement this with a sound understanding of the political and regulatory framework thus shaping the future of our health solutions.